Looking back on data analytics stocks' Q4 earnings, we examine this quarter's best and worst performers, including Health Catalyst (NASDAQ:HCAT) and its peers.
Organizations generate a lot of data that is stored in silos, often in incompatible formats, making it slow and costly to extract actionable insights, which in turn drives demand for modern cloud-based data analysis platforms that can efficiently analyze the silo-ed data.
The 5 data analytics stocks we track reported a weak Q4; on average, revenues beat analyst consensus estimates by 3.05%, while on average next quarter revenue guidance was 0.72% under consensus. Technology stocks have been hit hard on fears of higher interest rates as investors search for near-term cash flows and data analytics stocks have not been spared, with share prices down 13.9% since the previous earnings results, on average.
Slowest Q4: Health Catalyst (NASDAQ:HCAT)
Founded by healthcare professionals Tom Burton and Steve Barlow in 2008, Health Catalyst (NASDAQ:HCAT) provides data and analytics technology to healthcare organizations, enabling them to improve care and lower costs.
Health Catalyst reported revenues of $69.2 million, up 6.87% year on year, beating analyst expectations by 1.32%. It was a weak quarter for the company, with full year revenue guidance missing analysts' expectations.
“In the fourth quarter of 2022, I am pleased to share that we achieved strong performance across our business, including exceeding the mid-point of our quarterly guidance for both revenue and Adjusted EBITDA. For the full year 2022, I am also excited to share that our Adjusted EBITDA outperformed the mid-point of the original full year guidance we provided entering 2022, demonstrating continued operating leverage in our business despite lower annual revenue growth for 2022 as compared to our initial guidance for 2022.” said Dan Burton, CEO of Health Catalyst.
Health Catalyst delivered the slowest revenue growth of the whole group. The stock is down 19.1% since the results and currently trades at $11.31.
Read our full report on Health Catalyst here, it's free.
Best Q4: Alteryx (NYSE:AYX)
Initially created as a way to organise census data for the government, Alteryx (NYSE:AYX) provides software that helps companies automate and analyse their internal data processes.
Alteryx reported revenues of $301.1 million, up 73.2% year on year, beating analyst expectations by 7.79%. It was a decent quarter for the company, with exceptional revenue growth and guidance for the next year above analyst estimates.
Alteryx scored the strongest analyst estimates beat, fastest revenue growth, and highest full year guidance raise among its peers. The company added 18 customers to a total of 8,358. The stock is down 3.49% since the results and currently trades at $57.99.
Is now the time to buy Alteryx? Access our full analysis of the earnings results here, it's free.
Domo (NASDAQ:DOMO)
Founded by Josh James after selling his former business Omniture to Adobe, Domo (NASDAQ:DOMO) provides business intelligence software that allows managers to access and visualize critical business metrics in real-time, using their smartphones.
Domo reported revenues of $79.6 million, up 13.8% year on year, beating analyst expectations by 2.77%. It was a weak quarter for the company, with a full year guidance missing analysts' expectations and underwhelming guidance for the next year.
The stock is down 24.5% since the results and currently trades at $12.44.
Read our full analysis of Domo's results here.
Amplitude (NASDAQ:AMPL)
Born out of a failed voice recognition startup by founder Spenser Skates, Amplitude (NASDAQ:AMPL) is data analytics software helping companies improve and optimize their digital products.
Amplitude reported revenues of $65.3 million, up 32% year on year, beating analyst expectations by 2.63%. It was a weak quarter for the company, with a full year guidance missing analysts' expectations.
The company added 81 customers to a total of 1,994. The stock is down 30.5% since the results and currently trades at $11.64.
Read our full, actionable report on Amplitude here, it's free.
Palantir (NYSE:PLTR)
Started by Peter Thiel after seeing US defence agencies struggle in the aftermath of the 2001 terrorist attacks, Palantir (NYSE:PLTR) offers software as a service platform that helps government agencies and large enterprises use data to make better decisions.
Palantir reported revenues of $508.6 million, up 17.5% year on year, in line with analyst expectations. Despite the stock soaring on the results, it was a weak quarter for the company, with revenue guidance for the next quarter and the full year missing analysts' expectations.
Palantir had the weakest performance against analyst estimates and weakest full year guidance update among the peers. The stock is up 8.23% since the results and currently trades at $8.22.
Read our full, actionable report on Palantir here, it's free.
The author has no position in any of the stocks mentioned